SCHEMBL7188152

SCHEMBL7188152

Cc1cccc(C)c1C(=O)C(C(=O)OCCC(C)C)c1ccccc1.O=[PH3]

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MMP8 P22894 1/20 0.41
PPARG P37231 1/20 0.40
KCNA5 P22460 1/20 0.39
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
SCN8A Q9UQD0 1/20 0.36
CCR5 P51681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27485664 0.95 SLC22A1 (0.43) SLC22A1L3MBTL1MMP8PPARGKCNA5
SCHEMBL7184421 0.92 SLC22A1 (0.39) SLC22A1L3MBTL1MMP8PPARGCCR5
SCHEMBL7182458 0.90 SLC22A1 (0.41) SLC22A1L3MBTL1MMP8PPARGHTT
SCHEMBL7181368 0.87 SLC22A1 (0.39) SLC22A1L3MBTL1MMP8PPARGHTT
SCHEMBL27499050 0.87 SLC22A1 (0.39) SLC22A1L3MBTL1MMP8PPARGCCR5
SCHEMBL7180375 0.87 MMP8 (0.46) L3MBTL1MMP8ALDH1A1CHRM2CHRM4
SCHEMBL7180529 0.87 ALDH1A1 (0.45) L3MBTL1MMP8HTTALDH1A1CCR5
SCHEMBL27484637 0.86 SLC22A1 (0.42) SLC22A1L3MBTL1MMP8PPARGHTT
SCHEMBL7180656 0.86 SLC22A1 (0.42) SLC22A1MMP8PPARGHTTKDM4E
SCHEMBL7187321 0.85 SLC22A1 (0.40) SLC22A1L3MBTL1MMP8PPARGHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SLC22A1 2713/4885L3MBTL1 302/4885MMP8 4404/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SLC22A1 3188/4885L3MBTL1 126/4885MMP8 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.